Aurinia Pharmaceuticals/$AUPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Ticker
$AUPH
Sector
Primary listing
Employees
130
Headquarters
Edmonton, Canada
Website
AUPH Metrics
BasicAdvanced
$1.7B
30.48
$0.42
1.27
-
Price and volume
Market cap
$1.7B
Beta
1.27
52-week high
$12.90
52-week low
$6.55
Average daily volume
2.1M
Financial strength
Current ratio
5.225
Quick ratio
4.539
Long term debt to equity
19.271
Total debt to equity
24.405
Interest coverage (TTM)
13.91%
Profitability
EBITDA (TTM)
82.582
Gross margin (TTM)
80.16%
Net profit margin (TTM)
23.31%
Operating margin (TTM)
24.26%
Effective tax rate (TTM)
2.96%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
7.69%
Return on equity (TTM)
17.33%
Valuation
Price to earnings (TTM)
30.475
Price to revenue (TTM)
6.882
Price to book
5.07
Price to tangible book (TTM)
5.13
Price to free cash flow (TTM)
19.368
Free cash flow yield (TTM)
5.16%
Free cash flow per share (TTM)
0.661
Growth
Revenue change (TTM)
25.59%
Earnings per share change (TTM)
-219.83%
3-year revenue growth (CAGR)
43.57%
10-year revenue growth (CAGR)
99.46%
3-year earnings per share growth (CAGR)
-28.49%
10-year earnings per share growth (CAGR)
0.25%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
Bulls say / Bears say
Net product sales of LUPKYNIS reached $60.0 million in Q1 2025, a 25% increase year-over-year as adoption of the drug accelerates. (SEC)
Aurinia posted net income of $23.3 million in Q1 2025, reversing a $10.7 million loss from Q1 2024, demonstrating operating leverage after restructuring. (SEC)
The Phase 1 single-ascending-dose trial for aritinercept (AUR200) resulted in no Grade ≥3 or serious treatment-related adverse events and showed pharmacodynamic effects supportive of once-monthly dosing, significantly de-risking the pipeline's lead program. (Business Wire)
Cash, cash equivalents, restricted cash, and investments fell to $312.9 million as of March 31, 2025—down 13% from $358.5 million at the end of 2024—potentially reducing the funding available for clinical programs. (SEC)
In the AUR200 Phase 1 study, 24% of participants experienced injection site reactions, 11% reported headaches, and 7% developed upper respiratory tract infections, indicating possible tolerability challenges in future trials. (Business Wire)
Operating cash flow for Q1 2025 was modest at $1.3 million, highlighting ongoing dependence on milestone payments and external funding to support R&D. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
AUPH News
AllArticlesVideos
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Business Wire2 months ago
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
Business Wire2 months ago
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.7B as of September 17, 2025.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 30.48 as of September 17, 2025.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.